Gamma-Aminobutyric Acid (GABA)

Introduction

Gamma Aminobutyric Acid (Gaba) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

flowchart TD
    entities_gaba["Gamma-Aminobutyric Acid GABA"]
    style entities_gaba fill:#4fc3f7,stroke:#333,color:#000
    entities_gaba_0["Synthesis and Metabolism"]
    entities_gaba -->|"includes"| entities_gaba_0
    style entities_gaba_0 fill:#81c784,stroke:#333,color:#000
    entities_gaba_1["Biosynthesis"]
    entities_gaba -->|"includes"| entities_gaba_1
    style entities_gaba_1 fill:#ef5350,stroke:#333,color:#000
    entities_gaba_2["Vesicular Transport and Release"]
    entities_gaba -->|"includes"| entities_gaba_2
    style entities_gaba_2 fill:#ffd54f,stroke:#333,color:#000
    entities_gaba_3["Reuptake and Degradation"]
    entities_gaba -->|"includes"| entities_gaba_3
    style entities_gaba_3 fill:#ce93d8,stroke:#333,color:#000
    entities_gaba_4["GABA Receptors"]
    entities_gaba -->|"includes"| entities_gaba_4
    style entities_gaba_4 fill:#4fc3f7,stroke:#333,color:#000
    entities_gaba_5["GABA_A Receptors Ionotropic"]
    entities_gaba -->|"includes"| entities_gaba_5
    style entities_gaba_5 fill:#81c784,stroke:#333,color:#000

Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the mammalian central nervous system (CNS), counterbalancing excitatory glutamate signaling to maintain the excitation–inhibition (E/I) balance essential for normal brain function. Approximately 20–30% of all CNS neurons are GABAergic, including diverse populations of interneurons that regulate cortical and subcortical circuit activity ^{1Basic Neurochemistry: Molecular, Cellular and Medical Aspects (1999)1999Open reference}. ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}

Disruption of GABAergic neurotransmission is increasingly recognized as a key contributor to [neurodegenerative diseases, including alzheimers, huntington-pathway, parkinsons, and als. In alzheimers, the selective vulnerability of specific GABAergic interneuron subtypes—particularly somatostatin-positive (SST) interneurons—leads to network hyperexcitability, impaired oscillatory rhythms, and cognitive decline. Understanding the roles of GABA in health and disease has opened new avenues for therapeutic intervention in neurodegeneration ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}. ^{3Schwarcz R, Multiple GABA systems in Alzheimer's Disease brain (2021)2021 · DOI 10.3390/ijms222111677Open reference}

Synthesis and Metabolism

Biosynthesis

GABA is synthesized from glutamate by the enzyme glutamic acid decarboxylase (GAD), which exists in two isoforms: ^{4Astrocytic GABA release is a novel therapeutic target for Alzheimer's Disease (2014)2014 · DOI 10.1038/nature37531Open reference}

• GAD67 (GAD1): A 67-kDa cytoplasmic enzyme constitutively active throughout the cell; responsible for basal GABA production

• GAD65 (GAD2): A 65-kDa enzyme localized to synaptic terminals; activated on demand during neurotransmission and responsible for vesicular GABA pools

Both GAD isoforms require pyridoxal 5′-phosphate (PLP, a vitamin B6 derivative) as a cofactor. Dysregulation of GAD expression and activity has been documented in multiple neurodegenerative diseases, with reduced GAD67 mRNA levels observed in the hippocampus and cortex of alzheimers patients ^{3Schwarcz R, Multiple GABA systems in Alzheimer's Disease brain (2021)2021 · DOI 10.3390/ijms222111677Open reference}. ^{5Rudolph U, Mohler H, GABA A receptor subtypes: a new pharmacology (2004)2004 · DOI 10.1016/j.tips.2004.09.004Open reference}

Vesicular Transport and Release

After synthesis, GABA is loaded into synaptic vesicles by the vesicular GABA transporter (VGAT/SLC32A1), also known as vesicular inhibitory amino acid transporter (VIAAT). Upon arrival of an action potential and calcium influx, GABA is released into the synaptic cleft, where it binds to postsynaptic and presynaptic receptors. ^{6Cryan JF, Kaupmann K, GABA B receptors in neurodegeneration (2021)2021 · DOI 10.1016/j.tips.2021.01.003Open reference}

Reuptake and Degradation

GABA is cleared from the synaptic cleft primarily by membrane-bound GABA transporters (GATs), of which four subtypes exist (GAT-1 to GAT-3, and BGT-1). GAT-1, expressed on both neurons and astrocytes, is the most abundant. Tiagabine, a GAT-1 inhibitor, is used clinically as an antiepileptic drug. ^{7Hyperactivity of subicular parvalbumin interneurons drives early amyloid pathology and cognitive deficits in Alzheimer's Disease (2025)2025 · DOI 10.1038/s41380-025-03217-4Open reference}

Once taken up by astrocytes, GABA is catabolized by GABA transaminase (GABA-T) to succinic semialdehyde, which is further converted to succinate and enters the tricarboxylic acid (TCA) cycle. This metabolic pathway, known as the GABA shunt, links inhibitory neurotransmission to cellular energy metabolism. ^{8Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer's Disease (2022)2022 · DOI 10.1186/s40035-022-00300-6Open reference}

Notably, reactive astrocytes in alzheimers overexpress monoamine oxidase B (MAO-B), which produces GABA through an alternative pathway involving putrescine degradation. This astrocytic GABA release has been shown to tonically inhibit surrounding neurons, contributing to memory impairment in AD mouse models ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}0.

GABA Receptors

GABA exerts its effects through three receptor classes:

GABA_A Receptors (Ionotropic)

GABA_A receptors are ligand-gated chloride channels composed of pentameric subunit assemblies drawn from 19 subunit genes (α1–6, β1–3, γ1–3, δ, ε, θ, π, ρ1–3). The most common synaptic configuration is α1β2γ2, while extrasynaptic receptors (e.g., α5βγ2 or α4βδ) mediate tonic inhibition.

Key features in neurodegeneration:

• α5-containing GABA_A receptors: Enriched in the hippocampus, these extrasynaptic receptors mediate tonic inhibition and have been implicated in cognitive deficits in AD. Inverse agonists at α5-GABA_A receptors have shown procognitive effects in preclinical AD models ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}1

• Loss of GABA_A receptor subunits: Postmortem studies of AD brains show selective loss of specific GABA_A receptor subunits (α1, α5, β3) in the hippocampus and temporal cortex

• Benzodiazepine binding site: Modulated by benzodiazepines, barbiturates, and neurosteroids; the benzodiazepine binding site on GABA_A receptors (α/γ interface) is relatively preserved in AD, supporting continued clinical utility of these agents

GABA_B Receptors (Metabotropic)

GABA_B receptors are G protein-coupled receptors (Gi/Go) that form obligate heterodimers of GABA_B1 and GABA_B2 subunits. They mediate slow, prolonged inhibition by:

• Activating potassium channels (postsynaptic hyperpolarization)

• Inhibiting calcium channels (presynaptic reduction of neurotransmitter release)

• Suppressing adenylyl cyclase activity

GABA_B receptors are implicated in multiple neurodegenerative conditions. In AD, GABA_B receptor dysfunction contributes to network hyperexcitability and has been proposed as a therapeutic target ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}2. Baclofen, a GABA_B agonist, has shown neuroprotective properties in preclinical models of neurodegeneration.

GABA_C Receptors

Now reclassified as ρ-containing GABA_A receptors, these are primarily expressed in the retina and have limited involvement in neurodegenerative disease.

GABAergic Interneurons in the Brain

GABAergic interneurons represent approximately 20% of cortical neurons and are classified into molecularly and functionally distinct subtypes:

Parvalbumin (PV) Interneurons

PV interneurons are fast-spiking cells that provide perisomatic inhibition to pyramidal neurons, generating gamma oscillations (30–100 Hz) critical for working memory and attention. They include basket cells and chandelier (axo-axonic) cells. PV interneurons are ensheathed by perineuronal nets (PNNs), specialized extracellular matrix structures that provide neuroprotection.

In AD, PV interneurons show relative resilience compared to other interneuron subtypes, potentially due to PNN protection. However, PV interneuron hyperactivity in the subiculum has been shown to drive early amyloid pathology and cognitive deficits ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}3. Compensatory neuroplasticity in PV interneurons may help maintain executive function in early disease stages ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}4.

Somatostatin (SST) Interneurons

SST interneurons target the dendrites of pyramidal neurons, providing dendritic inhibition that modulates excitatory input integration and theta oscillations (4–12 Hz). They are the most vulnerable interneuron subtype in AD, exhibiting tau] inclusions, atrophy, and neuronal loss early in disease progression ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}5.

SST interneuron loss contributes to:

• Impaired dendritic computation in pyramidal neurons

• Disrupted theta oscillations in the hippocampus

• Disinhibition of cortical circuits, promoting hyperexcitability

• Reduced somatostatin peptide levels, which normally enhance neprilysin-mediated amyloid-beta degradation

Vasoactive Intestinal Peptide (VIP) Interneurons

VIP interneurons are disinhibitory cells that primarily inhibit other interneurons (SST and PV cells), thereby modulating cortical gain and state-dependent processing. Their role in neurodegeneration is less well characterized but is an area of active investigation.

Neuropeptide Y (NPY) and Cholecystokinin (CCK) Interneurons

NPY-expressing interneurons overlap with SST-expressing populations and are reduced in AD cortex. CCK interneurons are basket cells that provide perisomatic inhibition at cannabinoid receptor type 1 (CB1)-expressing synapses.

Role in Neurodegenerative Diseases

Alzheimer’s Disease

The relationship between GABAergic dysfunction and AD is multifaceted:

1. Excitation/Inhibition Imbalance: Loss of GABAergic interneurons and altered GABA receptor expression disrupts the E/I balance, producing network hyperexcitability. This manifests clinically as subclinical epileptiform activity, which occurs in 22–54% of AD patients and accelerates cognitive decline ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}6.

2. Oscillatory Disruption: Impaired gamma and theta oscillations due to interneuron dysfunction compromise memory encoding and retrieval. Gamma entrainment using 40 Hz sensory stimulation has emerged as a novel therapeutic approach, promoting microglia-mediated amyloid clearance and restoring neural oscillations ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}7.

Huntington’s Disease

Huntington’s disease (HD) is characterized by progressive loss of medium spiny neurons (MSNs) in the striatum, the primary GABAergic output of the basal ganglia. These MSNs, which express GABA and substance P or enkephalin, are particularly vulnerable to mutant huntingtin-protein toxicity. This differential vulnerability produces the characteristic choreiform movements of HD ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}8.

Mutant huntingtin-protein disrupts GABAergic neurotransmission through:

• Impaired GABA synthesis (reduced GAD expression)

• Altered GABA_A receptor trafficking and surface expression

• Disrupted mitochondrial function in MSNs

• Excitotoxic injury from excessive corticostriatal glutamate input

Parkinson’s Disease

In parkinsons, loss of dopamine input to the striatum disrupts the balance between direct and indirect basal ganglia pathways, both of which involve GABAergic transmission from the striatum. The resulting disinhibition of the subthalamic nucleus and excessive output from the globus pallidus internus/substantia-nigra pars reticulata produces the bradykinesia and rigidity characteristic of PD.

GABAergic dysfunction in PD also involves:

• Altered GABAergic interneuron function in the cortex

• Changes in GABA_A and GABA_B receptor expression in the basal-ganglia

• GABAergic involvement in levodopa-induced dyskinesia

Amyotrophic Lateral Sclerosis

Cortical hyperexcitability is an early feature of als, attributed in part to loss of GABAergic inhibition. Reduced cortical GABA levels, measured by magnetic resonance spectroscopy, correlate with disease progression and clinical disability.

Therapeutic Approaches Targeting GABA

Current Therapies

• Benzodiazepines: GABA_A receptor positive allosteric modulators used for epilepsy and anxiety in neurodegenerative disease patients; concerns about cognitive side effects limit use in dementia

• Vigabatrin: Irreversible GABA-T inhibitor that increases synaptic GABA; used in epilepsy

• Baclofen: GABA_B agonist with potential neuroprotective properties

• Tiagabine: GAT-1 inhibitor that prolongs GABAergic signaling

Emerging Therapeutic Strategies

1. α5-GABA_A receptor modulators: Negative allosteric modulators (inverse agonists) at α5-GABA_A receptors to reduce tonic inhibition and improve cognition in AD

2. MAO-B inhibitors for astrocytic GABA: KDS2010 and related compounds targeting reactive astrocyte-derived GABA overproduction; shown to reverse learning and memory impairment in AD mouse models ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}9

3. Gamma entrainment: 40 Hz light and sound stimulation to restore gamma oscillations; in clinical trials for AD (GENUS study, MIT)

4. Interneuron transplantation: Preclinical studies transplanting GABAergic interneuron precursors (medial ganglionic eminence-derived) to restore inhibitory circuit function in AD models

5. GABA_B receptor modulators: Positive allosteric modulators with improved therapeutic windows compared to direct agonists ^{2Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021)2021 · DOI 10.1016/j.phrs.2020.105314Open reference}0

6. Gene therapy: AAV-mediated delivery of GAD genes to restore local GABA production; explored in parkinsons (AAV-GAD trial for subthalamic nucleus)

GABA as a Biomarker

GABA levels can be measured non-invasively using magnetic resonance spectroscopy (MRS), specifically the MEGA-PRESS (Mescher-Garwood Point Resolved Spectroscopy) technique. Studies have shown:

• Reduced cortical GABA levels in alzheimers, correlating with cognitive impairment

• Decreased GABA in the [motor cortex[/brain-regions/motor-cortex of ALS patients, predicting disease progression

• Altered GABA/glutamate ratios in huntington-pathway striatum

• Potential utility of GABA MRS as a pharmacodynamic biomarker for GABAergic therapies in neurodegenerative disease

• Microglia](/genes/htt)

6. [Cryan JF, Kaupmann K. (2021). GABA B receptors in neurodegeneration. Trends in Pharmacological Sciences. PubMed)

7. [Bhatt DK, et al. (2025). Hyperactivity of subicular parvalbumin interneurons drives early amyloid pathology and cognitive deficits in Alzheimer’s Disease. Molecular Psychiatry. Full text)

8. [Huh CYL, Bhatt DK, et al. (2022). Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer’s Disease. Translational Neurodegeneration, 11, 26. Full text)

9. [Targa Dias Anastacio H, et al. (2020). Histological characterization of interneurons in Alzheimer’s Disease reveals a loss of somatostatin interneurons in the temporal cortex. Neuropathology and Applied Neurobiology. [PubMed)(https://pubmed.ncbi.nlm.nih.gov/32232904/)

10. [Xu Y, Bhati N, et al. (2020). GABAergic inhibitory interneuron deficits in Alzheimer’s Disease: implications for treatment. Frontiers in Neuroscience, 14, 660. [Full text)(https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00660/full)

11. [Amorim IS, et al. (2023). Factors affecting the GABAergic synapse function in Alzheimer’s Disease: Focus on microRNAs. Ageing Research Reviews. [ScienceDirect)(https://www.sciencedirect.com/science/article/pii/S1568163723002829)

12. [Ali AB, Islam T, Bhatt DK. (2023). The fate of interneurons, GABAA receptor sub-types and perineuronal nets in Alzheimer’s Disease. Brain Pathology, 33(4), e13129. Wiley)

• --

External Links

• National Institute on Aging (NIA)

• Alzheimer’s Association

• Michael J. Fox Foundation for Parkinson’s Research

• ALS Association

• Cure Huntington’s Disease Initiative (CHDI)

• National Institute of Neurological Disorders and Stroke (NINDS)

Background

The study of Gamma Aminobutyric Acid (Gaba) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: Gamma-Aminobutyric Acid expression search

• Allen Mouse Brain Atlas: Gamma-Aminobutyric Acid search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• BrainSpan Developmental Transcriptome: Gamma-Aminobutyric Acid developmental expression